Psoriasis Pathophysiology: Current Concepts of Pathogenesis

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2005 Feb 15

PMID 15708932

Citations 106

Authors

J G Krueger

A Bowcock

Affiliations

Soon will be listed here.

Abstract

Psoriasis vulgaris is a common skin disorder characterised by focal formation of inflamed, raised plaques that constantly shed scales derived from excessive growth of skin epithelial cells. The disease is defined by a series of linked cellular changes in the skin: hyperplasia of epidermal keratinocytes, vascular hyperplasia and ectasia, and infiltration of T lymphocytes, neutrophils, and other types of leucocyte in affected skin. In a relatively short period, psoriasis vulgaris has been conceptualised as a T lymphocyte mediated autoimmune disease and new biological therapies that target T cells have just entered routine clinical practice. Similarly, rapid progress has been made towards dissecting cellular and molecular pathways of inflammation that contribute to disease pathogenesis. This short review presents current pathogenic concepts that have emerged from genetic, genomic, and cellular information obtained in basic studies and from clinical studies of selective immune targeting drugs.

Citing Articles

Exploring the Relationship Between Psychiatric Illness and Dermatological Disorders: A Narrative Review.

Kaye A, Islam R, Castine A, Wester G, Barham W, Nguyen C Cureus. 2025; 17(2):e78731.

PMID: 40065888 PMC: 11892542. DOI: 10.7759/cureus.78731.

Pharmacotherapy of arterial hypertension in patients with psoriasis.

Dodulik J, Dodulikova L, Plasek J, Ramik Z, Vrtal J, Vaclavik J J Hypertens. 2025; 43(4):568-576.

PMID: 39976197 PMC: 11872270. DOI: 10.1097/HJH.0000000000003982.

Regulation of epidermal barrier function and pathogenesis of psoriasis by serine protease inhibitors.

Wang J, Li J, Zhou L, Hou H, Zhang K Front Immunol. 2024; 15:1498067.

PMID: 39737188 PMC: 11683130. DOI: 10.3389/fimmu.2024.1498067.

Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments.

Manzari Tavakoli G, Yazdanpanah N, Rezaei N Adv Rheumatol. 2024; 64(1):61.

PMID: 39169436 DOI: 10.1186/s42358-024-00401-y.

The Perspective of Cannabidiol in Psoriasis Therapy.

Stanescu A, Bejan G, Balta M, Andronic O, Toma C, Busnatu S Psoriasis (Auckl). 2024; 14:51-61.

PMID: 38911997 PMC: 11193997. DOI: 10.2147/PTT.S469698.

References

Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V . A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet. 2002; 32(4):666-9. DOI: 10.1038/ng1020. View

Rottman J, Smith T, Ganley K, Kikuchi T, Krueger J . Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest. 2001; 81(3):335-47. DOI: 10.1038/labinvest.3780242. View

Olofsson P, Holmberg J, Tordsson J, Lu S, Akerstrom B, Holmdahl R . Positional identification of Ncf1 as a gene that regulates arthritis severity in rats. Nat Genet. 2002; 33(1):25-32. DOI: 10.1038/ng1058. View

Buchler T, Hajek R, Bourkova L, Kovarova L, Musilova R, Bulikova A . Generation of antigen-loaded dendritic cells in a serum-free medium using different cytokine combinations. Vaccine. 2003; 21(9-10):877-82. DOI: 10.1016/s0264-410x(02)00535-2. View

Curry J, Qin J, Bonish B, Carrick R, Bacon P, Panella J . Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med. 2003; 127(2):178-86. DOI: 10.5858/2003-127-178-IIRRIN. View

Zhou X, Krueger J, Kao M, Lee E, Du F, Menter A . Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics. 2003; 13(1):69-78. DOI: 10.1152/physiolgenomics.00157.2002. View

Lebwohl M . Psoriasis. Lancet. 2003; 361(9364):1197-204. DOI: 10.1016/S0140-6736(03)12954-6. View

Kopp T, Lenz P, Bello-Fernandez C, Kastelein R, Kupper T, Stingl G . IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J Immunol. 2003; 170(11):5438-44. DOI: 10.4049/jimmunol.170.11.5438. View

Gottlieb A, Chaudhari U, Mulcahy L, Li S, Dooley L, Baker D . Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003; 48(6):829-35. DOI: 10.1067/mjd.2003.307. View

10.

Xia Y, Li B, Hylton D, Detmar M, Yancopoulos G, Rudge J . Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood. 2003; 102(1):161-8. DOI: 10.1182/blood-2002-12-3793. View

11.

Victor F, Gottlieb A . TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol. 2003; 1(3):264-75. View

12.

Krueger G, Callis K . Development and use of alefacept to treat psoriasis. J Am Acad Dermatol. 2003; 49(2 Suppl):S87-97. DOI: 10.1016/mjd.2003.552. View

13.

Rahman P, Bartlett S, Siannis F, Pellett F, Farewell V, Peddle L . CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet. 2003; 73(3):677-81. PMC: 1180694. DOI: 10.1086/378076. View

14.

Villadsen L, Schuurman J, Beurskens F, Dam T, Dagnaes-Hansen F, Skov L . Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest. 2003; 112(10):1571-80. PMC: 259129. DOI: 10.1172/JCI18986. View

15.

Lebwohl M, Tyring S, Hamilton T, Toth D, Glazer S, Tawfik N . A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003; 349(21):2004-13. DOI: 10.1056/NEJMoa030002. View

16.

Leonardi C, Powers J, Matheson R, Goffe B, Zitnik R, Wang A . Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003; 349(21):2014-22. DOI: 10.1056/NEJMoa030409. View

17.

Tokuhiro S, Yamada R, Chang X, Suzuki A, Kochi Y, Sawada T . An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet. 2003; 35(4):341-8. DOI: 10.1038/ng1267. View

18.

Helms C, Cao L, Krueger J, Wijsman E, Chamian F, Gordon D . A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet. 2003; 35(4):349-56. DOI: 10.1038/ng1268. View

19.

Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S . Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature. 2003; 426(6965):454-60. DOI: 10.1038/nature02119. View

20.

Gordon K, Papp K, Hamilton T, Walicke P, Dummer W, Li N . Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003; 290(23):3073-80. DOI: 10.1001/jama.290.23.3073. View